Comparison of Mortality and Clinical Failure Rates Between Vancomycin and Teicoplanin in Patients with Methicillin-resistant Staphylococcus Aureus Pneumonia

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2022 Jul 7

PMID 35799129

Authors

Jang Ho Lee

Myeong Geun Choi

Hyung Jun Park

Ho Cheol Kim

Chang-Min Choi

Affiliations

Soon will be listed here.

Abstract

Background: Very few studies have compared the effects and side effects of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. This study aimed to compare the efficacy and safety of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia.

Methods: This study examined 116 patients with methicillin-resistant Staphylococcus aureus pneumonia who met the inclusion criteria and were treated with either vancomycin (n = 54) or teicoplanin (n = 62). The primary (i.e., clinical failure during treatment) and secondary outcomes (i.e., mortality rates, discontinuation of study drugs due to treatment failure, side effects, and clinical cure) were evaluated.

Results: The vancomycin group presented lower clinical failure rates (25.9% vs. 61.3%, p < 0.001), discontinuation due to treatment failure (22.2% vs. 41.9%, p = 0.024), and mortality rates (3.7% vs 19.4%, p = 0.010). The Cox proportional hazard model revealed that teicoplanin was a significant clinical failure predictor compared with vancomycin (adjusted odds ratio, 2.198; 95% confidence interval 1.163-4.154). The rates of drug change due to side effects were higher in the vancomycin group than in the teicoplanin group (24.1% vs. 1.6%, p < 0.001).

Conclusions: Vancomycin presented favorable treatment outcomes and more side effects compared with teicoplanin, which suggests that clinicians would need to consider the efficacy and potential side effects of these drugs before prescription.

Citing Articles

A rare occurrence of Vancomycin-induced gastrointestinal hemorrhage without thrombocytopenia: a case report and literature review.

Wen Y, Chen Y, Xiao G BMC Infect Dis. 2024; 24(1):1105.

PMID: 39367298 PMC: 11451159. DOI: 10.1186/s12879-024-09949-y.

References

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

Vardakas K, Matthaiou D, Falagas M . Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J. 2009; 34(5):1148-58. DOI: 10.1183/09031936.00041009. View

Welte T, Pletz M . Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents. 2010; 36(5):391-400. DOI: 10.1016/j.ijantimicag.2010.06.045. View

Cappelletty D, Jablonski A, Jung R . Risk factors for acute kidney injury in adult patients receiving vancomycin. Clin Drug Investig. 2014; 34(3):189-93. DOI: 10.1007/s40261-013-0163-0. View

Mukhopadhyay J . Teicoplanin for treating MRSA pneumonia. BMJ. 2014; 348:g2317. DOI: 10.1136/bmj.g2317. View

Peng Y, Ye X, Li Y, Bu T, Chen X, Bi J . Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials. PLoS One. 2013; 8(11):e79782. PMC: 3832583. DOI: 10.1371/journal.pone.0079782. View

Lamer C, de Beco V, Soler P, Calvat S, Fagon J, Dombret M . Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993; 37(2):281-6. PMC: 187653. DOI: 10.1128/AAC.37.2.281. View

Scheetz M, Wunderink R, Postelnick M, Noskin G . Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2006; 26(4):539-50. DOI: 10.1592/phco.26.4.539. View

10.

Drusano G, Preston S, Fowler C, Corrado M, Weisinger B, Kahn J . Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004; 189(9):1590-7. DOI: 10.1086/383320. View

11.

Rodvold K, George J, Yoo L . Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011; 50(10):637-64. DOI: 10.2165/11594090-000000000-00000. View

12.

Chen J, Luo Y, Zhang S, Liang Z, Wang Y, Zhang Y . Community-acquired necrotizing pneumonia caused by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a Chinese teenager: case report and literature review. Int J Infect Dis. 2014; 26:17-21. DOI: 10.1016/j.ijid.2014.02.025. View

13.

Chawla L, Amdur R, Faselis C, Li P, Kimmel P, Palant C . Impact of Acute Kidney Injury in Patients Hospitalized With Pneumonia. Crit Care Med. 2017; 45(4):600-606. DOI: 10.1097/CCM.0000000000002245. View

14.

Roberts J, Stove V, De Waele J, Sipinkoski B, McWhinney B, Ungerer J . Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents. 2014; 43(5):423-30. DOI: 10.1016/j.ijantimicag.2014.01.023. View

15.

Gursel G, Aydogdu M, Ozyilmaz E, Ozis T . Risk factors for treatment failure in patients with ventilator-associated pneumonia receiving appropriate antibiotic therapy. J Crit Care. 2008; 23(1):34-40. DOI: 10.1016/j.jcrc.2007.12.015. View

16.

Lameire N, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum J . Acute kidney injury: an increasing global concern. Lancet. 2013; 382(9887):170-9. DOI: 10.1016/S0140-6736(13)60647-9. View

17.

Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View

18.

Abdul-Aziz M, Alffenaar J, Bassetti M, Bracht H, Dimopoulos G, Marriott D . Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020; 46(6):1127-1153. PMC: 7223855. DOI: 10.1007/s00134-020-06050-1. View

19.

Cavalcanti A, Goncalves A, Almeida C, Bugano D, Silva E . Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010; (6):CD007022. DOI: 10.1002/14651858.CD007022.pub2. View

20.

Butler M, Hansford K, Blaskovich M, Halai R, Cooper M . Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014; 67(9):631-44. DOI: 10.1038/ja.2014.111. View